FDA: MedWatch

• Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib): Drug Safety Communication - Due to Rare but Severe Lung Inflammation September 13, 2019
  FDA is warning that Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) used to treat some patients with advanced breast cancers may cause rare but severe inflammation of the lungs.
  FDA
• Zantac (ranitidine): Safety Information - NDMA Found in Samples of Some Ranitidine Medicines September 13, 2019
  FDA has learned that some ranitidine medicines, including some products commonly known as the brand-name drug Zantac, contain NDMA.
  FDA
• Tetrahydrocannabinol (THC)-containing Vaping Products: Vaping Illnesses September 9, 2019
  Consumers are likely aware of the recent reports of respiratory illnesses – including some resulting in deaths – following the use of vaping products.The FDA is working closely with the CDC, as well as state and local public health partners to investigate them as quickly as possible.
  FDA
• E-Cigarette Products: Safety Communication - Due to the Incidents of Severe Respiratory Disease Associated with Use of an E-Cigarette Product August 30, 2019
  Both the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention are working tirelessly to investigate the distressing incidents of severe respiratory disease associated with use of e-cigarette products.
  FDA